Impax Laboratories

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Impax Laboratories ( IPXL) is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products. This stock is trading up 6.7% at $20.16 in recent trading.

Today's Volume: 858,000

Average Volume: 534,669

Volume % Change: 137%

Shares of IPXL are soaring today after the company announced it obtained the U.S. rights to AstraZeneca PLC's migraine headache drug Zomig.

From a technical standpoint, IPXL bounced big right off its 50-day moving average today at $19.41, and it briefly traded above its 200-day moving average of $20.64 on big volume.

Market players should now watch for the next big breakout trade to trigger in IPXL once this stock moves above $21.68 to $22.07 with volume. Look for volume that's near or above 534,669 if we that breakout soon.

Impax shows up on recent lists of 8 Pharma Stocks to Watch and 5 Bargain Biotech Stocks.

If you liked this article you might like

Shares of Distressed Rex Energy Jump with Asset Sale

Rex Energy (REXX) Is Today's Strong On High Volume Stock

Here’s Why Rex Energy (REXX) Stock is Plunging Today

Rex Energy (REXX) Flagged As Strong On High Volume

Weak On High Volume: Rex Energy (REXX)